Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and
Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Participants with
Previously Treated Hepatocellular Unresectable Carcinoma.